Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: Evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound

Bone

Volumn 33, Issue 4, 2003, Pages 575-581

  Frediani, B ^a   Falsetti, P ^a   Baldi, F ^a   Acciai, C ^a   Filippou, G ^a   Marcolongo, R ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bone mineral density; Clodronate; Corticosteroid induced osteoporosis; Quantitative ultrasound; Vertebral fractures

Indexed keywords

CALCIUM; CLODRONIC ACID; CORTICOSTEROID; PREDNISONE; VITAMIN D;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BONE DENSITY; BONE MINERAL; BONE STRENGTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DENSITOMETRY; DISEASE PREDISPOSITION; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FEMALE; FEMUR NECK; FEMUR SHAFT; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PROPHYLAXIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 0141996220     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(03)00208-4     Document Type: Article

References (34)

1. Adinoff A.D., Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 309:1983;265-268.
2. Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis pathogenesis and management . Ann Intern Med. 112:1990;352-364.
3. Kholsa S., Lufkin E.E., Fitzpatrick L.A., Melton L.J. III. Epidemiology and clinical features of osteoporosis in young individuals. Bone. 15:1994;551-555.
4. Dempster D., Arlot M., Meunier P. Mean wall thikness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int. 35:1983;410-417.
5. Sewell K. Modern therapeutic approaches to osteoporosis. Rheum Dis Clin North Am. 15:1983;583-614.
6. Nordin B.E.C., Marshall D.H., Francis R.M., Crilly R.G. The effect of sex steroid and corticosteroid hormone on bone. J Steroid Biochem. 15:1981;171-174.
7. Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edouard C, Darby AJ. Histomorphometric profile, pathophysiology and reversibility corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1:303-11;1079.
8. Manolagas S.C. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 14:(7):1999;1061-1066. Review.
9. Silverman S.L. Management of corticosteroid-induced osteoporosis a clinician's perspective . Calcif Tissue Int. 50:1992;101-103.
10. LoCascio V., Bonucci E., Imbimbo B., Ballanti P., Adami S., Milani S., Tartarotti D., DellaRocca C. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 8:1990;39-51.
11. Adachi J.D., Papaioannou A. Corticosteroid-induced osteoporosis detection and management . Drug Safety. 24:(8):2001;607-624. Review.
12. Blair M.M., Carson D.S., Barrington R. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis. J. Fam. Pract. 49:(9):2000;839-848. Review.
13. Reid I.R., King A.R., Alexander C.J., Ibbertson H.K. Prevention of steroid-induced osteoporosis with (3-amino-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet. 1:1988;143-146.
14. Adachi J.D., Cranney A., Goldsmith C.H., et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol. 21:1994;1922-1926.
15. Herrala J., Puolijoki H., Liippo K., Raitio M., Impivaara O., Tala E., Nirminen M.M. Clodronate is effective in preventing corticosteroid-induced bone loss among asthatic patients. Bone. 22:(5):1998;577-582.
16. Adachi J.D., Saag K.G., Delmass P.D., Liberman U.A., Emkey R.D., Seeman E., Lane N.E., Kaufman J.M., Poubelle P.E., Hawkins F., Correa-Rotter R., Menker C.J., Rodriguez-Portales J.A., Schnitzer T.J., Block J.A., Wing J., McIlwain H.H., Westhovens R., Brown J., Melo-Gomes J.A., Gruber B.L., Yanover M.J., Leite M.O., Siminoski K.G., Nevitt M.C., Sharp J.T., Malice M.P., Dumortier T., Czachur M., Carofano W., Daifotis A. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids a randomized, double-blind, placebo-controlled extension trial . Arthritis Rheum. 44:(1):2001;202-211.
17. Wallach S., Cohen S., Reid D.M., Hughes R.A., Hosking D.J., Laan R.F., Doherty S.M., Maricic M., Rosen C., Brown J., Barton I., Chines A.A. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 67:(4):2000;277-285.
18. Lau H.S., Beuning K.s, Postma-Lim E., Klein-Beernink L., de Boer A., Porsius A.J. Non-compliance in elderly people evaluation of risk factors by longitudinal data analysis . Phamacy World Sci. 18:1996;63-68.
19. Giannini S., D'Angelo A., Malvasi L., et al. Effects of one year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 14:1993;137-141.
20. Rossini M., Braga V., Gatti D., Gerardi D., Zamberlan N., Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone. 24:1999;125-129.
21. Frediani B., Allegri A., Ronconi S., Bisogno S., Porfidio G., Falsetti P., Storri L., Marcolongo R. Clodronate in the treatment and prevention of osteoporosis efficacy of 100 mg i.m. once a week . Bone. 22:(3):1998;58S.
22. Filipponi P., Cristallini S., Rizzello E., et al. Cyclical intravenous clodronate in postmenopausal osteoporosis results of a long-term trial . Bone. 18:1996;179-184.
23. McCloskey E.V., Selby P., De Takats D., Bernard J., Davies M., Robinson J., Francis R., Adams J., Pande K., Beneton M., Jalava T., Loyttyniemi E., Kanis J.A. Effects of clodronate on vertebral fracture risk in osteoporosis a 1-year interim analysis . Bone. 28:(3):2001;310-315.
24. Lufkin E.G., Argueta R., Whitaker M.D., Cameron A.L., Wong V.H., Egan K.S., O'Fallon W.M., Riggs B.L. Pamidronate an unrecognized problem in gastrointestinal tolerability . Osteoporosis Int. 4:1994;320-322.
25. DeGroen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J., Pinkas H., Wang K.K. Esophagitis associated with the use of alendronate. N Engl J Med. 335:1996;1016-1021.
26. Siris E.S., Chines A.A., Altman R.D., Brown J.P., Johnston C.C. Jr., Lang R., McClung M.R., Mallette L.E., Miller P.D., Ryan W.G., Singer F.R., Tucci J.R., Eusebio R.A., Bekker P.J. Risedronate in the treatment of Paget's disease of bone an open label, multicenter study . J Bone Miner Res. 13:1998;1032-1037.
27. Balena R., Toolan B.C., Shea M., Markatos A., Myers EeR, Lee S.C., Opas E.E., Seedor J.G., Klein H., Frankenfield D., Quartuccio H.A., Fioravanti C., Clair J., Brown E., Hayes W.C., Rodan G.A. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized non-human primates. J Clin Invest. 92:1993;2577-2586.
28. McCloskey E.V., Spector T.D., Eyres K.S., Fern E.D., O'Rourke N., Vasikaran S., Kanis J.A. The assessment of vertebral deformity a method for use in population studies and clinical trials . Osteoporosis Int. 3:(3):1993;138-147.
29. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., Felsenberg D., Recker R.R., Tonino R.P., Roux C., Pinchera A., Foldes A.J., Greenspan S.L., Levine M.A., Emkey R., Santora A.C. II, Kaur A., Thompson D.E., Yates J., Orloff J.J. for the Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res. 12:(1):2000;1-12.
30. Filipponi P., Cristallini S., Policani G., Schifini M.F., Casciari C., Garinei P. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass. Bone. 26:(3):2000;269-274.
31. Frediani B., Allegri A., Falsetti P., Baldi F., Bisogno S., Storri L., Marcolongo R. Effects of clodronate (100 mg/once a week) on heel stiffness and axial BMD in prevention of corticosteroid induced osteoporosis. J Bone Miner Res. 15:(1):2000;S553.
32. Muratore M., Santacesaria G., Quarta E., Calcagnile F., Cosentino L., Muratore L. Prevention with clodronate of osteoporosis secondary to inhaled corticosteroid treatment in patients with chronic asthmatic bronchitis. Int J Pharmacol Res. 20:(3-4):2000;61-64.
33. Spector T.D., McCloskey E.V., Doyle D.V., Kanis J.A.A. Prevalence of vertebral fracture in women and the relationship with bone density and symptoms the Chingford Study . J Bone Miner Res. 8:1993;817-822.
34. Prins S.H., Jorgensen H.L., Jorgensen L.V., Hassager C. The role of quantitative ultrasound in the assessment of bone a review . Clin Physiol. 18:(1):1998;3-17. Review.